Cannabis Science will expand scope of sponsored research to include neurological conditions
Cannabis Science, Inc. (OTC: CBIS), a U.S.-based company that develops cannabinoid-based medicines, has revealed its plans to broaden the extent of its sponsored medical cannabis research in Nigeria.
Neurological conditions, such as Post-Traumatic Stress Disorder (PTSD), will be added to its research.
CBIS’s research is being conducted following the receipt of U.S. Patent Number 9,763,991 for “Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders, and PTSD, among other target indications.”
“We are encouraged with the preliminary results from our pre-clinical work and animal studies in Nigeria,” stated CBIS’ President, CEO, and Co-founder, Mr. Raymond C. Dabney. He added that “Our work in Nigeria, while independent of our research collaborations in the U.S., contributes significantly to the Global Consortium we launched last year.”
Specific cannabinoids will be used for Cannabis Science’s research
At the current time, CBIS is working closely with its research collaborator to explore the prospective positive effects of cannabidiol or CBD when used in animal studies and clinical trials for the treatment of oxidative stress, psychosis, and oro-bucco-lingual dyskinesias.
According to CBIS’ plans to expand the scope of its sponsored research in Nigeria, cannabis plant extracts containing a cannabinoid called CBN will be combined with various other cannabinoids to determine their efficacy at treating neurobehavioral disorders. Methods of extraction will also be looked into.
About Cannabis Science, Inc.
The main goal of Cannabis Science is to research and develop a cannabinoid-based medicine that gains the all-important seal of approval from the U.S. Food and Drug Administration (FDA).
Three primary elements are combined into Cannabis Science’s drug development program:
- Defining the therapeutic potential and specificity of cannabinoids being tested
- Identifying and analyzing different drug delivery mechanisms
- Testing and evaluating the application of additional diagnostic and/or therapeutic procedures to participants in the company’s randomized controlled trials, as well as the impact of co-interventions.
“The research may be of use in other movement disorders, such as Huntington’s Disease, Tourette’s Syndrome, Cerebral Palsy, and Dystonia. These could be related through the neurotransmitter, dopamine, modulated by the CB1 receptors. While we will continue our research in regard to oro-bucco-lingual dyskinesias, oxidative stress, and psychosis, we believe there is an opportunity to expand our research in Nigeria to include PTSD,” said Mr. Dabney.
“Specifically, we will develop a protocol for a PTSD clinical study immediately and begin this study as soon as possible. This will allow the company to leverage our patent for compositions of cannabinol (CBN), as well as our expertise with other cannabinoids.”
Eventually, the company hopes to tackle numerous medical conditions with natural cannabis-based treatments, including certain types of cancer, chronic pain, chronic obstructive pulmonary disease (COPD) autism, epilepsy, HIV/AIDS, Parkinson’s Disease, sleeping disorders and now, neurological conditions, too.
